The AI in Business Podcast Commercial Solutions in Life Sciences from a Data Perspective - with Jane Chen of Novartis
Aug 7, 2024
In this discussion, Jane Chen, Director of Commercial Analytics for Women’s Cancer at Novartis, shares her expertise on the hurdles in identifying patient groups with rare diseases. She emphasizes the impact of HIPAA regulations on data privacy and the challenges posed by fragmented data sources. Jane also highlights the innovative potential of generative AI in transforming patient experiences, insisting on the importance of integrating commercial data to improve healthcare workflows. Her insights shine a light on the evolving landscape of life sciences analytics.
AI Snips
Chapters
Transcript
Episode notes
Challenges in Patient Identification
- Identifying niche patient segments in healthcare is challenging due to incomplete and biased datasets.
- Multiple fragmented data sources are necessary to approximate patient identification and care provider mapping.
Healthcare Data Privacy Limitations
- Healthcare data privacy, governed by HIPAA, imposes significant 'blinders' by restricting patient identifiability.
- This contrasts industries like finance where consumer data is more accessible, creating inherent data limitations in healthcare.
Tech Enables Better Data Integration
- Advances in technology and computing power now enable faster, cheaper integration and modeling of large healthcare data sets.
- This progress allows filling in data blind spots that previously hindered commercial analytics in life sciences.